almagate has been researched along with Aging in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cannon, E | 1 |
| Michels, S; Rosenfeld, PJ; Schmidt-Erfurth, U | 1 |
| Bailey, C; Imrie, FR | 1 |
| Behar-Cohen, F; Berdugo, M; Sennlaub, F | 1 |
| Covell, CA; Graziano, JA; Rich, D; Tobin, KA | 1 |
| Goldstein, M; Leibovitch, I; Loewenstein, A; Waisbourd, M | 1 |
3 review(s) available for almagate and Aging
| Article | Year |
|---|---|
Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
Topics: Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost-Benefit Analysis; Humans; Intravitreal Injections; Macular Degeneration; Managed Care Programs; Medicare; Off-Label Use; Pharmaceutical Services; Professional Role; Quality-Adjusted Life Years; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; United States; Vascular Endothelial Growth Factor A; Vision Disorders | 2019 |
Promising new treatments for neovascular age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Capillary Permeability; Cholestanols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Design; Drugs, Investigational; Eye Proteins; Humans; Injections; Lactates; Macular Degeneration; Models, Animal; Multicenter Studies as Topic; Neovascularization, Pathologic; Nerve Growth Factors; Pigment Epithelium of Eye; Protein Isoforms; Randomized Controlled Trials as Topic; RNA Interference; RNA, Small Interfering; Serpins; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vitreous Body | 2006 |
Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Delivery Systems; Humans; Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
3 other study(ies) available for almagate and Aging
| Article | Year |
|---|---|
New treatments for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
[Age-related macular degeneration: therapeutic hopes].
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Double-Blind Method; Female; Genetic Predisposition to Disease; Humans; Macular Degeneration; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
New outlook for age-related macular degeneration.
Topics: Aged; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Fluorescein Angiography; Humans; Light Coagulation; Macular Degeneration; Nursing Assessment; Patient Education as Topic; Photochemotherapy; Ranibizumab; Tomography, Optical Coherence | 2007 |